Scientific deep-dive

GLP-1 Side Effects: A Plain-English Guide to What the Trials Actually Showed

Nausea was more common on semaglutide in STEP 1 than on tirzepatide in SURMOUNT-1. Side-by-side trial rates of nausea, vomiting, pancreatitis, gallbladder and thyroid events for semaglutide, tirzepatide, orforglipron and liraglutide.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
14 min read·8 citations

This investigation is part of Weight Loss Rankings' living editorial database — 1,160+ research articles and 630+ editorially reviewed GLP-1 telehealth providers, sourced only from primary FDA labels and peer-reviewed PubMed literature.

Most plain-English coverage of GLP-1 side effects either understates the gut issues most patients actually experience or overstates the rare risks (pancreatitis, thyroid cancer) that almost never occur in practice. This article does neither. We pulled the actual adverse-event tables from the STEP-1 (semaglutide) and SURMOUNT-1 (tirzepatide) Phase 3 trials, plus the 2025 FDA-approved prescribing labels for Wegovy and Zepbound, and walk through each side effect category with verified percentages. Every percentage is cited to its source PMID. Bonus: a counterintuitive finding the lay press has missed. See also our lab-result explainers: elevated lipase/amylase and triglycerides on a GLP-1.

Related deep-dive: Victoza (liraglutide 1.8 mg) evidence review — the first daily GLP-1, FDA-approved 2010, with Hikma 2024 and Teva 2025 generics now on the market.
Find your week: our side-effect timeline tool shows when each side effect peaks and resolves, by drug and week, with every cell anchored to a primary source (FDA label or pivotal trial publication).

The dominant signal: GI side effects from semaglutide (STEP-1)

STEP-1 randomized 1,961 adults with BMI ≥ 30 (or ≥ 27 with weight comorbidities) to weekly semaglutide 2.4 mg or placebo for 68 weeks [1]. The published adverse-event table is unambiguous about where the safety burden actually sits: in the gut.

Adverse eventSemaglutide 2.4 mgPlacebo
Any GI adverse event74.2%47.9%
Nausea44.2%17.4%
Diarrhea31.5%15.9%
Vomiting24.8%6.6%
Discontinued due to GI side effects4.5%0.8%

Read across the rows: nearly half of patients on semaglutide experienced nausea at some point during the trial. Roughly a quarter experienced vomiting. These aren't fringe outcomes — they're what most patients should expect. The good news is that only 4.5% of trial participants discontinued specifically because of GI side effects (7.0% stopped for any adverse event), which means the vast majority of the GI symptoms were mild-to-moderate and resolved with continued use, especially as the dose escalation phase ended [1]. For practical strategies to keep nausea manageable during titration, see our GLP-1 nausea management guide.

SURMOUNT-1: tirzepatide adverse events at three doses

SURMOUNT-1 randomized 2,539 adults to weekly tirzepatide at 5 mg, 10 mg, or 15 mg, or placebo, for 72 weeks [2]. The trial reported adverse events separately for each dose tier, which lets us see the dose-response curve directly. Per-symptom rates below are from the Zepbound prescribing information’s pooled SURMOUNT-1 and SURMOUNT-2 table [6]; the discontinuation row is SURMOUNT-1 [2]:

Adverse eventTirz 5 mgTirz 10 mgTirz 15 mgPlacebo
Nausea25%29%28%8%
Diarrhea19%21%23%8%
Vomiting8%11%13%2%
Constipation17%14%11%5%
Discontinued due to AE4.3%7.1%6.2%2.6%

The counterintuitive finding: semaglutide had higher nausea than tirzepatide

Magnitude comparison

Trial-reported GI adverse-event rates at the top trial dose — semaglutide 2.4 mg (STEP-1, 68 wk) vs tirzepatide 15 mg (Zepbound label pool of SURMOUNT-1 and SURMOUNT-2). All values are the proportion of trial participants who reported at least one event during the trial period.[1][2][6]

  • Nausea — semaglutide 2.4 mg (STEP-1)44.2 %
  • Nausea — tirzepatide 15 mg (SURMOUNT-1/-2 label pool)28.0 %
  • Diarrhea — semaglutide 2.4 mg (STEP-1)31.5 %
  • Vomiting — semaglutide 2.4 mg (STEP-1)24.8 %
  • Diarrhea — tirzepatide 15 mg (SURMOUNT-1/-2 label pool)23.0 %
  • Vomiting — tirzepatide 15 mg (SURMOUNT-1/-2 label pool)13.0 %
  • Constipation — tirzepatide 15 mg (SURMOUNT-1/-2 label pool)11.0 %
  • Discontinuation due to AE — tirzepatide 15 mg6.2 %
    vs 2.6% placebo (SURMOUNT-1)
  • Discontinuation due to AE — semaglutide 2.4 mg7.0 %
    vs 3.1% placebo (STEP-1, all adverse events)
Trial-reported GI adverse-event rates at the top trial dose — semaglutide 2.4 mg (STEP-1, 68 wk) vs tirzepatide 15 mg (Zepbound label pool of SURMOUNT-1 and SURMOUNT-2). All values are the proportion of trial participants who reported at least one event during the trial period.

Cross-comparing the two tables produces a result that contradicts the conventional lay-press assumption that “tirzepatide is harder on the gut.”

At the top doses tested in these trials, semaglutide 2.4 mg had 44.2% nausea and 24.8% vomiting [1], while tirzepatide 15 mg had 28% nausea and 13% vomiting [6]. Semaglutide's GI burden is materially higher, particularly for vomiting, where the absolute risk difference vs placebo is about 18 percentage points versus about 11 for tirzepatide.

Two important caveats before drawing strong conclusions from this:

  1. No head-to-head trial. STEP-1 and SURMOUNT-1 recruited different populations, ran for different durations (68 vs 72 weeks), and used different dose escalation schedules. Comparing across trials is suggestive, not conclusive.
  2. STEP-1 used a faster escalation. Semaglutide STEP-1 escalated from 0.25 mg to 2.4 mg over 16 weeks (a relatively rapid 4-week increment ladder), while SURMOUNT-1 tirzepatide used a 4-week increment from 2.5 mg up. Faster escalation correlates with higher GI symptom burden in both drug classes — so part of the gap may be protocol-driven, not drug-driven.

That said, the practical takeaway for patients is that tirzepatide is not obviously worse for the gut than semaglutide, and may actually be modestly better-tolerated at maximum dose. For patients sensitive to nausea, the dose escalation schedule matters more than the choice between the two drugs.

All four approved obesity drugs, side by side

Two more drugs now complete the FDA-approved set: orforglipron (Foundayo), the first small-molecule (non-peptide) oral GLP-1 pill, approved in 2026 on the ATTAIN-1 trial[7], and the older injectable liraglutide (Saxenda), approved on SCALE[8]. Putting all four together at their top maintenance dose gives the single reference comparison — with one important rule: these are four separate trials, not a head-to-head, so read the columns as within-trial drug-vs-placebo differences, not as validated rankings between drugs. Each column is the top maintenance dose in that drug's pivotal obesity trial: semaglutide 2.4 mg (Wegovy, STEP 1), tirzepatide 15 mg (Zepbound, SURMOUNT-1), orforglipron 36 mg in the trial, sold as the 17.2 mg tablet (Foundayo, ATTAIN-1), and liraglutide 3.0 mg (Saxenda, SCALE). "Stopped due to side effects" is all-cause adverse-event discontinuation.

Adverse eventSemaglutideTirzepatideOrforglipronLiraglutide
Nausea44.2%28%33.7%40.2%
Vomiting24.8%13%24.0%16.3%
Diarrhea31.5%23%23.1%20.9%
Stopped due to side effects7.0%6.2%10.3%9.9%

The bottom row is the one that matters most, because it captures how many people the side effects actually drove off the drug. Read against placebo, the gap was widest for the two drugs newest to this table: orforglipron 10.3% vs 2.7% and liraglutide 9.9% vs 3.8%, compared with semaglutide 7.0% vs 3.1% and tirzepatide 6.2% vs 2.6%. In other words, the once-weekly injectables (tirzepatide, then semaglutide) kept the most patients on treatment; the oral pill and the once-daily liraglutide had the highest dropout — orforglipron's higher vomiting rate (24%) is a big part of why, and daily dosing gives liraglutide more chances to provoke symptoms.

Two caveats before ranking anything. First, semaglutide's per-symptom rates here are from STEP 1, tirzepatide's from the Zepbound label pool of SURMOUNT-1 and SURMOUNT-2; orforglipron's and liraglutide's serious-event and gallbladder figures partly come from pooled FDA-label data rather than the single pivotal trial. Second, titration schedule and trial duration differed across all four (SCALE 56 weeks, STEP 1 and SURMOUNT-1/ATTAIN-1 68-72 weeks), and faster escalation raises GI burden independent of the drug. For the full weight-loss and outcome numbers behind each of these trials, see our GLP-1 trial results database; for the oral pill's profile in depth, our Foundayo side-effects guide.

Pancreatitis: a real warning, but not a real signal

Both Wegovy and Zepbound carry FDA labeling that lists acute pancreatitis as a possible adverse reaction. The Wegovy label states: “Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including WEGOVY.” Patients are instructed to discontinue if pancreatitis is suspected.

The actual numerical risk in clinical trials is much smaller than the warning language implies. In the pooled Zepbound weight-management trials, acute pancreatitis was reported in 0.2% of tirzepatide-treated and 0.2% of placebo-treated patients [6]. A 2023 systematic review and meta-analysis of 9 randomized controlled trials including 6,828 tirzepatide recipients found that an increased risk of pancreatitis was NOT statistically associated with tirzepatide (RR 1.46, 95% CI 0.59–3.61, p = 0.436) [5]. The relative risk point estimate is elevated but the confidence interval crosses 1.0, which means the trial-level evidence cannot rule out either a small real effect or no effect at all.

Translation: the FDA pancreatitis warning is a regulatory precaution based on the GLP-1 mechanism (these drugs do increase pancreatic enzyme exposure) and a small number of post-marketing case reports. The randomized trial data does not show a statistically meaningful elevation. The practical risk for any individual patient is real but very small, and prescribers appropriately screen for prior pancreatitis history before starting therapy.

Gallbladder events: a smaller signal that IS statistically real

Gallbladder disease is a different story. The Zepbound label reports cholelithiasis (gallstones) in 1.1% of tirzepatide recipients vs 1.0% of placebo and cholecystitis (gallbladder inflammation) in 0.7% vs 0.2% [6]. The 2023 meta-analysis confirmed that the composite of gallbladder or biliary disease WAS significantly associated with tirzepatide compared with placebo or basal insulin (RR 1.97, 95% CI 1.14–3.42) [5].

The FDA label notes the proximate cause: “Acute gallbladder events were associated with weight reduction” [6]. In other words, the gallbladder signal is most likely a consequence of rapid weight loss in general (any major weight loss, regardless of mechanism, increases gallstone risk because of cholesterol mobilization from fat stores), not a drug-specific toxicity. This is consistent with the same pattern seen after bariatric surgery, very-low-calorie diets, and other rapid-weight-loss interventions.

Thyroid C-cell tumor warning: rodent-only evidence

Both Wegovy and Zepbound carry a black-box warning about medullary thyroid carcinoma (MTC). The warning is based on rodent studies showing dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant plasma exposures [6]. The Zepbound label is explicit: “It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide- induced rodent thyroid C-cell tumors has not been determined” [6].

No human MTC cases have been reported in the published Phase 3 obesity trials for either semaglutide or tirzepatide. Both drugs are contraindicated in patients with personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), which is the appropriate precaution given the rodent signal.

Practically: if you don't have a personal or family history of thyroid cancer, the rodent thyroid signal is not a meaningful clinical concern. If you do, both drugs are off the table. Our deep dive on GLP-1s and thyroid cancer evidence walks through the rodent-to-human translation in detail.

Hypoglycemia: low risk, with one important exception

GLP-1 receptor agonists are glucose-dependent insulin secretagogues — they only stimulate insulin release when blood glucose is elevated, which provides built-in protection against hypoglycemia in monotherapy. STEP-1 reported hypoglycemia in just 0.6% of semaglutide-treated participants, comparable to the placebo rate [1].

The exception is patients who take semaglutide or tirzepatide alongside insulin or sulfonylureas. Combination therapy dramatically increases hypoglycemia risk (16–30% across various trials), which is why prescribers typically lower insulin or sulfonylurea doses when initiating a GLP-1.

Injection site reactions

Injection site reactions were reported in 6% to 8% of tirzepatide recipients (vs 2% on placebo) in the pooled SURMOUNT-1 and SURMOUNT-2 data in the Zepbound prescribing information [6]. Most were mild to moderate (transient redness, itching, or small bruise at the injection site) and did not lead to treatment discontinuation. Injection technique matters — rotating injection sites, allowing the injectable to reach room temperature before use, and using a fresh needle each time all reduce the rate.

“Ozempic face”: not actually a documented adverse event

The widely-reported “Ozempic face” phenomenon — facial volume loss, skin laxity, and accelerated facial aging in people on GLP-1 therapy — is real, but it's not a documented adverse event in any Phase 3 trial. It's a cosmetic consequence of rapid weight loss, not a drug-specific toxicity. Approximately 20– 50% of weight lost on GLP-1 therapy comes from lean mass, including facial subcutaneous fat — see our investigation of semaglutide and lean mass loss for the trial-data background on the body composition question.

The phenomenon affects every drug that produces dramatic weight loss, including bariatric surgery, very-low-calorie diets, and other GLP-1 / GIP/GLP-1 agonists (dulaglutide, liraglutide, tirzepatide). It's not unique to semaglutide despite the nickname. The clinical literature characterizes it as a real cosmetic outcome of rapid lean-mass loss, not as a safety signal. For people concerned about it, the published mitigation strategies are slower dose escalation (slower weight loss trajectory), increased dietary protein, and resistance training to preserve lean mass.

Bottom line: how to think about GLP-1 safety

  1. The dominant safety burden is GI symptoms during dose escalation. 40–73% of patients experience nausea, diarrhea, or vomiting at some point. Most are mild-to-moderate and resolve. About 4–7% of patients discontinue because of side effects.
  2. Pancreatitis warning is regulatory, not statistical. The randomized trials do not show a significant pancreatitis signal beyond placebo. The warning exists because the mechanism is plausible and post-marketing case reports accumulate at the population level.
  3. Gallbladder signal is real but small, and is mostly a consequence of rapid weight loss. 0.7% cholecystitis on tirzepatide vs 0.2% on placebo.
  4. Thyroid warning is rodent-only. No human MTC signal in Phase 3 trials. Contraindicated only in patients with personal or family history of MTC or MEN 2.
  5. Hypoglycemia risk is essentially zero in monotherapy and substantial when combined with insulin or sulfonylurea.
  6. “Ozempic face” is real but not a drug adverse event. It's lean-mass loss from rapid weight reduction, common to every effective weight loss intervention.

For most patients without specific contraindications, the safety ceiling on GLP-1 weight loss therapy is GI tolerance during dose escalation. The serious-but-rare risks (pancreatitis, MTC) are either statistically insignificant in the trial data or based on non-human evidence. The cosmetic concerns (facial volume, sarcopenia) are functions of rapid weight loss in general and can be mitigated by slower dose escalation and dietary protein.

For our editorial coverage of how to choose between providers offering compounded versions of these drugs, see the semaglutide provider rankings and the tirzepatide provider rankings. For the head-to-head efficacy comparison between the two drugs beyond just side effects, see our tirzepatide vs semaglutide head-to-head deep dive. Three deeper FDA-label-specific dives go below the headline AE table: the gallbladder / biliary disease deep dive on cholelithiasis and the He et al meta-analysis; GLP-1 + ileus and bowel obstruction on the 2023 FDA postmarketing label addition and the symptom profile that distinguishes ileus from ordinary nausea; and GLP-1 + levothyroxine on the 33% AUC interaction the Wegovy and Rybelsus labels call out for patients on thyroid replacement.

Further reading

Frequently Asked Questions

Gastrointestinal side effects dominate. STEP-1 reported nausea (44% on semaglutide vs 17% placebo), diarrhea (~31%), constipation (~23%), and vomiting (~25%). SURMOUNT-1 reported similar rates for tirzepatide. Most are mild-to-moderate and concentrated in the first 4-8 weeks. Discontinuation rates due to adverse events were approximately 6-7% in both trials.
About 6-7% in both STEP-1 (semaglutide 2.4 mg) and SURMOUNT-1 (tirzepatide 15 mg). The vast majority of patients tolerated the maintenance dose. Slow titration, dose reduction (from the maintenance dose to the previous step), and supportive care for nausea help most patients stay on the drug.
Both have small numerical signals in trials but neither has been definitively established as causal. The thyroid C-cell tumor signal comes from rodent studies and led to the FDA boxed warning; human studies have not confirmed an increased risk. Pancreatitis has a small numerical excess in some trials, generally accepted as a low-frequency adverse event. Patients with personal or family history of medullary thyroid carcinoma or MEN 2 syndrome should not use GLP-1s.
In its ATTAIN-1 trial, orforglipron's GI rates were broadly in the same range as the injectables (nausea ~34%, diarrhea ~23%), but its vomiting rate (~24%) was closer to semaglutide's than tirzepatide's, and more patients stopped because of adverse events (10.3%) than on tirzepatide (6.2%) or semaglutide (7.0%). Liraglutide (Saxenda), the once-daily injection, had a similar ~10% discontinuation rate. These are separate trials, not head-to-head, but the pattern is that tirzepatide kept the most patients on treatment.
Counterintuitively, no. Side effect rates between tirzepatide 15 mg and semaglutide 2.4 mg are similar in their pivotal trials, and at the highest doses tirzepatide actually had slightly LOWER nausea rates than semaglutide. Both drugs share the GI side effect profile characteristic of GLP-1 receptor activation.
Most GI side effects are concentrated in the first 4-8 weeks and at each new dose escalation. By the time patients reach the maintenance dose, side effects have substantially diminished or resolved for the majority. A small subset experiences ongoing nausea or constipation requiring management strategies. Severe persistent symptoms warrant a conversation with the prescriber about dose reduction or alternative drugs.
Gallbladder disease is the one serious adverse event for which the trial data shows a statistically significant signal - unlike pancreatitis, where the confidence interval in the meta-analyses crosses 1.0, the gallbladder risk is real and confirmed. The Zepbound prescribing information reports cholelithiasis (gallstones) in 1.1 percent of tirzepatide recipients versus 1.0 percent on placebo, and cholecystitis (gallbladder inflammation) in 0.7 percent versus 0.2 percent on placebo - roughly a threefold difference for cholecystitis - and a 2023 meta-analysis confirmed that the composite of gallbladder or biliary disease was significantly elevated with tirzepatide versus placebo or basal insulin. The FDA label is explicit about the likely mechanism: acute gallbladder events were associated with weight reduction, not with a drug-specific toxic effect, which is consistent with the same gallstone risk seen after bariatric surgery and very-low-calorie diets, where rapid cholesterol mobilization from fat stores promotes stone formation. The absolute risk is still small at the individual level, but it is real enough that patients should be aware of the symptoms - right upper abdominal pain that may radiate to the shoulder or back, especially after a fatty meal, accompanied by nausea - and should contact their prescriber promptly if those develop while on a GLP-1.

References

  1. 1.Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID: 33567185.
  2. 2.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID: 35658024.
  3. 3.Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021. PMID: 33755728.
  4. 4.Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. 2024. PMID: 38078870.
  5. 5.Zeng Q, Xu J, Mu X, Shi Y, Fan H, Li S. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023. PMID: 37908750.
  6. 6.Eli Lilly and Company. ZEPBOUND (tirzepatide) Prescribing Information. DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  7. 7.Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med. 2025. PMID: 40960239.
  8. 8.Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes). N Engl J Med. 2015. PMID: 26132939.

Saxenda Side Effects (2026): What's Common, What's Serious & How to Manage Them

Saxenda (liraglutide 3 mg) most often causes nausea, diarrhea, constipation, vomiting and injection-site reactions. Serious label risks include pancreatitis, gallbladder disease, kidney injury, a faster heart rate and a thyroid C-cell boxed warning.

11 min read

GLP-1 Drugs for Children Under 12: Trial Results, Prescribing Trends and FDA Limits

No GLP-1 drug is FDA-approved for weight loss in children under 12, but a 56-week trial found liraglutide lowered BMI in 6- to 11-year-olds and prescribing is rising. What parents should know about the evidence, side effects, label limits and open questions.

8 min read

Saxenda & Victoza (Liraglutide) and Erectile Dysfunction: The Evidence

Liraglutide (Saxenda, Victoza) offers a real but modest erectile benefit. Obesity and diabetes drive ED through endothelial dysfunction that weight loss can reverse, and liraglutide's weight loss is smaller (~8% in SCALE). There is also a positive signal in hypogonadal men.

9 min read

Saxenda & Victoza (Liraglutide) and Sex Drive: The Honest Evidence

No liraglutide trial measures libido. Saxenda and Victoza are the older, once-daily GLP-1 with smaller weight loss (~8% in SCALE) than Ozempic or Zepbound, so any sex-drive effect is weight-loss-mediated and more modest. Men and women, explained.

9 min read

How to Get Saxenda Online (2026): The Daily Liraglutide Pathways & Cost

Saxenda is daily liraglutide 3 mg — the original weight-loss GLP-1. How to get it online in 2026: legitimate telehealth pathways, cost by pathway, Saxenda vs the weekly GLP-1s (Wegovy/Zepbound), and safety.

9 min read

Saxenda (Liraglutide) for Weight Loss: FDA Label, SCALE Trial Evidence, and the New Teva Generic (2026)

Saxenda (liraglutide 3 mg daily) produced −8.0% weight loss vs −2.6% on placebo in SCALE. Generic liraglutide 3 mg has been FDA-approved since August 27, 2025, and Novo Nordisk is discontinuing the Saxenda brand in early 2027. Wegovy and Zepbound lose more.

13 min read

Where to get tirzepatide (Mounjaro / Zepbound) safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

8.1

Oak

Compounded semaglutide and tirzepatide at a low starting price, with a full price list before you sign up

Read full review →

From $250/mo (starting dose)

Get started →
7.8

SnagRx

Compounded semaglutide and tirzepatide at a flat lifetime price

Read full review →

From $149/mo

Get started →
7.1

AgelessRx

Longevity-focused GLP-1 care with microdosing and brand-name options

Read full review →

From $209/mo (2-month plan rate)

Get started →